Adriana Bonansea Frances, MD
Allergy & Immunology · Homestead, FLNPI 1356522155
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,328 of the $18,313 with a category attached, or 83.7%. 33 manufacturers reported payments, led by Sanofi at 26.1% of the total. 2025 is the largest year on record at $4,384, 2.1 times the $2,056 reported in 2019.
Across 537 payments — averaging $34.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$2K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- CSL Behring$2K
- plus $5K from 27 others
What the payments were for
- Consulting fees$2,76615%
- Food & beverage$15,32884%
- Education$2191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 62 | $4,777 |
| Regeneron Healthcare Solutions, Inc. | 55 | $2,074 |
| AstraZeneca | 66 | $1,922 |
| GSK | 66 | $1,685 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $1,624 |
| CSL Behring | 56 | $1,561 |
| Pharming Healthcare, Inc. | 16 | $700 |
| Genentech USA, Inc. | 15 | $579 |
| Biocryst US Sales Co., LLC | 32 | $549 |
| Grifols USA, LLC | 21 | $411 |
| Novartis | 15 | $365 |
| Amgen(2 entities) | 12 | $294 |
| Teva Pharmaceuticals USA, Inc. | 5 | $237 |
| Lilly USA, LLC | 4 | $204 |
| Shire North American Group Inc | 8 | $193 |
| Optinose US, Inc. | 7 | $159 |
| Pfizer | 7 | $146 |
| Genentech, Inc. | 1 | $139 |
| Otsuka America Pharmaceutical, Inc. | 1 | $98 |
| Octapharma USA, Inc. | 4 | $93 |
| Hikma Pharmaceuticals USA | 4 | $65 |
| Ionis Pharmaceuticals, Inc. | 2 | $63 |
| Biocryst Pharmaceuticals, Inc. | 2 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $54 |
| AbbVie | 2 | $45 |
| Merck | 2 | $39 |
| Boehringer Ingelheim | 2 | $39 |
| Alk-abello, Inc | 2 | $34 |
| Galderma Laboratories, L.p. | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $20 |
| USWM, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$718
- RUCONEST$347
- TRELEGY ELLIPTA$246
- NUCALA$240
- Haegarda$224
- XOLAIR$139
- HYQVIA$125
- FASENRA$124
- Austedo XR$122
- JOENJA$114
How this compares
$18,313 in reported general payments places this provider in the 80th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 69 | $198,959 |
| Dupixent SyringeDupilumab | 30 | $122,393 |
| TezspireTezepelumab-Ekko | 11 | $46,106 |
| NucalaMepolizumab | 12 | $43,712 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $37,110 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,113 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,391 |
| Arnuity ElliptaFluticasone Furoate | 27 | $8,714 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,840 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,511 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,383 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $2,969 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 17 | $1,977 |
| Epinephrine | 14 | $1,960 |
| Azelastine Hcl | 63 | $1,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $139 | $198,95969 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,685 | $86,930101 claims |
| AstraZenecaTezspire, Symbicort | $1,922 | $51,94631 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,624 | $37,11018 claims |
| Hikma Pharmaceuticals USAEpinephrine | $65 | $1,96014 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $22 | $34618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Homestead
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.